Disease · MONDO_0043693

alcoholic liver disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. alcoholic liver disease. Diseases, record MONDO_0043693. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0043693

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: alcoholic liver disease; Open Targets
Open Targets ID: MONDO_0043693; Open Targets
Other names: alcoholic liver diseases; Open Targets
Disease Ontology: DOID:0070658; Disease Ontology
MeSH: D008108; MeSH
NCI Thesaurus: C34783; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 7 drugs, from ClinicalTrials.gov; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ACETYLCYSTEINE	CHEMBL600	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
ADEMETIONINE	CHEMBL1088977	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
GUSELKUMAB	CHEMBL2364648	Antibody	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
HYALURONATE SODIUM	CHEMBL4594244		Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
NALTREXONE	CHEMBL19019	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
LARSUCOSTEROL	CHEMBL4802158	Small molecule	Unknown	USAN	1	0	0	Drugs and targets
LARSUCOSTEROL SODIUM	CHEMBL4802246	Small molecule	Unknown	USAN	1	0	0	Drugs and targets

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
IL12B	Interleukin-23	1	Interleukin-23 inhibitor	Phase 1	https://conductscience.org/library/genes/3593	Drugs and targets
IL23A	Interleukin-23	1	Interleukin-23 inhibitor	Phase 1	https://conductscience.org/library/genes/51561	Drugs and targets
OPRD1	Opioid receptors; mu/kappa/delta	1	Opioid receptors; mu/kappa/delta antagonist	Unknown	https://conductscience.org/library/genes/4985	Drugs and targets
OPRK1	Opioid receptors; mu/kappa/delta	1	Opioid receptors; mu/kappa/delta antagonist	Unknown	https://conductscience.org/library/genes/4986	Drugs and targets
OPRM1	Opioid receptors; mu/kappa/delta	1	Opioid receptors; mu/kappa/delta antagonist	Unknown	https://conductscience.org/library/genes/4988	Drugs and targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00573313	Effects of SAMe in Patients With Alcoholic Liver Disease	Phase 3	94	2013-06-10	Liver Disease, Alcoholic	ADEMETIONINE	Its record names the disease	ClinicalTrials.gov
NCT04391764	Effect of Naltrexone in Achieving and Maintaining Abstinence From Alcohol in Patients With Cirrhosis.	Not applicable	100		Liver Cirrhosis	NALTREXONE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT05018481	HA35 Moderate Alcoholic Hepatitis (AH) Study	Early phase 1	54		Alcoholic Hepatitis	HYALURONATE SODIUM	Its record names the disease	ClinicalTrials.gov
NCT04736966	Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease	Phase 1	13		Alcoholic Liver Disease	GUSELKUMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
S-adenosylmethionine (SAMe) Treatment vs Sugar Pill Placebo: serious adverse events	0 of 18	0 of 19	37	NCT00573313

Source Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22044287	RESULT	1	PubMed
20561703	RESULT	1	PubMed
42615276	DERIVED	1	PubMed
41494657	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0043693

GET https://conductscience.org/api/diseases/v1/MONDO_0043693/drugs

API reference For AI assistants